Eli Lilly and Company (NYSE:LLY) Shares Down 2.2% – Here’s Why

Posted by Stanley Muller on Sep 10th, 2026

Eli Lilly and Company logo Eli Lilly and Company (NYSE:LLY – Get Free Report) shares fell 2.2% on Tuesday . The company traded as low as $1,113.55 and last traded at $1,123.60. 2,272,672 shares changed hands during mid-day trading, a decline of 26% from the average session volume of 3,060,302 shares. The stock had previously closed at $1,149.36.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Lilly plans to use cash generated by its GLP-1 medicines to invest in women’s health, potentially broadening its growth profile beyond obesity and diabetes treatments. Lilly’s GLP-1 Windfall to Fund Push Into Women’s Health
Positive Sentiment: Recent coverage highlights GLP-1 growth approaching 50% annually, strong demand and a pipeline that could convert today’s incretin revenue into future product launches. Lilly’s deliberate rationing of some launches also underscores how demand has exceeded available supply, while capacity expansion could support additional revenue. What Eli Lilly Was Telling You While It Rationed Its Own Launches Eli Lilly’s Pipeline in 2026
Neutral Sentiment: Analysts and investment commentary remain constructive on Lilly’s medium-term prospects, but comparisons with Nvidia emphasize that investors are weighing two high-growth stories and must decide whether Lilly’s obesity-drug opportunity justifies its premium valuation. Got $10,000? Eli Lilly vs. Nvidia
Negative Sentiment: With Lilly now valued above $1 trillion, investors are questioning how much future GLP-1 growth is already reflected in the shares. Recent weakness and the stock’s elevated earnings multiple increase sensitivity to disappointing sales, competition or slower adoption. Eli Lilly Stock Has Become a Trillion-Dollar Giant. Is It Too Late to Buy?
Negative Sentiment: Ongoing litigation involving a seller of weight-loss drugs remains a potential overhang, even as the case has been narrowed. Earlier market commentary also pointed to Lilly underperforming the broader market during a recent session, reflecting continued valuation and risk concerns. Eli Lilly Lawsuit Against Weight-Loss Drug Seller Gets Another Shave

Wall Street Analyst Weigh In

LLY has been the topic of a number of research analyst reports. HSBC boosted their target price on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research report on Thursday. Leerink Partners lifted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Wolfe Research reiterated an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Cantor Fitzgerald increased their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Finally, Bank of America raised their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a report on Friday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,295.39.

View Our Latest Stock Analysis on LLY

Eli Lilly and Company Price Performance

The company’s 50-day moving average is $1,187.24 and its 200-day moving average is $1,072.08. The firm has a market capitalization of $1.06 trillion, a price-to-earnings ratio of 37.68, a PEG ratio of 1.39 and a beta of 0.50. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company’s revenue was up 47.7% on a year-over-year basis. During the same quarter last year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts expect that Eli Lilly and Company will post 36.35 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s payout ratio is 23.22%.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald Zakrowski sold 2,000 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by company insiders.

Institutional Trading of Eli Lilly and Company

Several large investors have recently added to or reduced their stakes in LLY. Coastal Bridge Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth about $2,959,000. Mosaic Family Wealth Partners LLC grew its stake in Eli Lilly and Company by 70.6% in the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after purchasing an additional 1,430 shares in the last quarter. Generali Investments Management Co LLC grew its stake in Eli Lilly and Company by 17.5% in the second quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock worth $12,258,000 after purchasing an additional 1,521 shares in the last quarter. Moran Wealth Management LLC increased its holdings in Eli Lilly and Company by 85.6% in the second quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock valued at $25,072,000 after buying an additional 9,638 shares during the last quarter. Finally, Amundi increased its holdings in Eli Lilly and Company by 9.9% in the first quarter. Amundi now owns 5,055,025 shares of the company’s stock valued at $4,649,464,000 after buying an additional 454,549 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.